Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: AstraZeneca AB, SE-151 85 Södertälje, Sweden
Fasenra 30 mg solution for injection in pre-filled syringe.
Fasenra 30 mg solution for injection in pre-filled pen.
| Pharmaceutical Form |
|---|
|
Solution for injection (injection) in pre-filled syringe. Solution for injection (injection) in pre-filled pen (Fasenra Pen). Clear to opalescent, colourless to yellow solution and may contain translucent or white to off-white particles. |
Pre-filled syringe: Each pre-filled syringe contains 30 mg benralizumab* in 1 mL.
Pre-filled pen: Each pre-filled pen contains 30 mg benralizumab* in 1 mL.
* Benralizumab is a humanised monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Benralizumab |
Benralizumab is an anti-eosinophil, humanised afucosylated, monoclonal antibody (IgG1, kappa). It specifically binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα). The IL-5 receptor is specifically expressed on the surface of eosinophils and basophils. The absence of fucose in the Fc domain of benralizumab results in high affinity for FcɣRIII receptors on immune effector cells such as natural killer (NK) cells. This leads to apoptosis of eosinophils and basophils through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), which reduces eosinophilic inflammation. |
| List of Excipients |
|---|
|
Histidine |
Pre-filled syringe:
One mL solution in a single-use pre-filled syringe made from type I glass with a staked 29-gauge ½-inch (12.7 mm) stainless steel needle, rigid needle shield, and Fluorotec-coated plunger stopper in a passive safety device.
Pack containing 1 pre-filled syringe.
Pre-filled pen:
One mL solution in a sterile, single use pre-filled pen made from type I glass with staked 29-gauge ½-inch (12.7 mm) stainless steel needle, rigid needle shield, and Fluorotec-coated stopper in a pre-filled pen.
Pack containing 1 pre-filled pen.
AstraZeneca AB, SE-151 85 Södertälje, Sweden
EU/1/17/1252/001 1 pre-filled syringe
EU/1/17/1252/002 1 pre-filled pen
Date of first authorisation: 8 January 2018
Date of latest renewal: 15 September 2022
| Drug | Countries | |
|---|---|---|
| FASENRA | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
